Financial Disclosure

Seoul – September 17, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.

Toronto – September 17, 2026 -- Franco-Nevada Corporation has agreed to a A$200 million (approximately $144 million) follow-on financing package with Minerals 260 Limited to advance the Bullabulling Gold Project in Western Australia, lifting its total backing of the project to an aggregate A$420 million (approximately $300 million).

The package comprises a A$170 million (approximately $122 million) gross royalty acquisition and a A$30 million (approximately $22 million) equity subscription as lead order in a future Minerals 260 capital raise.

Hong Kong – September 17, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Ivonescimab extends median survival to 30.8 months in head-to-head trial

In the intention-to-treat population of the HARMONi-2 study (AK112-303), patients treated with ivonescimab monotherapy achieved a median overall survival (OS) of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73; 95% CI: 0.57–0.95; P=0.009). The data cutoff was September 17, 2026, with a median follow-up of 36 months and 234 OS events recorded. Professor Caicun Zhou, principal investigator and IASLC President, is scheduled to deliver the full oral presentation on September 15.

Austin, Texas – September 17, 2026 -- Oracle Corporation (NYSE: ORCL) confirmed that Executive Chair and Chief Technology Officer Larry Ellison has cancelled his 10b5-1 trading plan to sell company stock, halting a scheduled divestment before any shares changed hands.

Ellison cancels stock sale plan with zero shares sold

Oracle stated no stock was sold under the now-terminated 10b5-1 plan. The company added that Ellison currently has no other arrangements in place to sell any of his Oracle shares.

Los Angeles – September 17, 2026 -- Adventist Health White Memorial and Adventist Health White Memorial Montebello generate more than $1.2 billion in annual economic activity and support approximately 5,500 jobs across Los Angeles County, according to a new study.

Study quantifies hospitals' role as economic anchors serving 2.4 million residents

The analysis, conducted by the Los Angeles County Economic Development Corporation (LAEDC), examined the two hospitals' functions as healthcare providers, employers, and community anchors. Combined, they serve more than 2.4 million residents across their primary and secondary service areas.

Newark, Del. – September 17, 2026 -- Xanh Entertainment Inc. is pursuing a $2.5 million seed funding round to scale EscapeSquid, its platform linking virtual stationary cycling with fitness studios, local events and destination travel.

Xanh Entertainment targets $2.5 million to build fitness-to-travel infrastructure

John Phung, Founder and CEO of Xanh Entertainment Inc., said the proposed seed round is intended to fund technology development and partnerships across fitness, hospitality and travel sectors. The capital would support a model designed to move participants from at-home virtual rides into studio classes, local experiences, regional events and destination travel.

Quebec – September 17, 2026 -- Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) expects its common shares and warrants to begin trading on NYSE American LLC as early as September 17, 2026, under the ticker symbols "DHGR" and "DHGR WS."

Devonian pursues dual listing tied to underwritten public offering

The proposed NYSE American listing is connected to an underwritten public offering of Devonian's common shares and warrants. The company will retain its existing listing on the TSX Venture Exchange and has reserved the symbol "DHGR" there, with plans to later change its TSXV ticker from "GSD" to "DHGR."

Listing remains contingent on NYSE American's final authorization

Trading commencement on NYSE American depends on market conditions and final approval of Devonian's listing application, as well as the company's continued compliance with exchange rules.

Nashville, Tenn. – September 17, 2026 -- XLCS Partners, Inc. served as buyside advisor to CID Capital on its investment in Kaiser Garage Doors & Gates, LLC, a deal that closed on September 17, 2026.

CID Capital completes third platform investment from its latest fund

The Kaiser transaction marks the third platform investment from CID Capital Opportunity Fund IV, L.P. CID Capital, based in Indianapolis, Indiana, is a private equity firm that takes control positions in lower middle market companies, focusing on founder- and family-owned businesses.

Kaiser brings 30-plus years of regional operations across Arizona

Headquartered in Tucson, Arizona, Kaiser installs and services residential and commercial overhead doors and gates across the Phoenix, Tucson, and White Mountains markets. The company has built its footprint over more than three decades, establishing long-standing customer relationships in the region.

Basel – September 17, 2026 -- CordenPharma is committing €80 million in multi-year capital expenditure to expand aseptic fill-finish capacity at its FDA- and EMA-approved Caponago site near Milan, targeting total production capacity of up to 500 million sterile injectable units annually.

New 11,000-square-meter facility adds over 50% to site footprint

A key milestone within the total investment was the €13 million acquisition of a new 11,000 m2 commercial building and an adjacent 26,000 m2 plot next to the existing advanced-phase fill-finish area. The expansion, completed September 17, 2026, increases the facility's overall footprint by more than 50%.

Golden, Colo. – September 17, 2026 -- PlanetiQ has been named an industry partner under NOAA's new Space-Based Environmental Monitoring (SBEM) Indefinite Delivery, Indefinite Quantity contract, a vehicle running from September 17, 2026, through September 17, 2026, with a five-year base period and a five-year option.

NOAA opens new decade-long contract vehicle for commercial satellite data

The SBEM IDIQ, established by NOAA's National Environmental Satellite, Data, and Information Service (NESDIS) through its Commercial Data Program, will let PlanetiQ compete for task orders covering two data types: Global Navigation Satellite System-Radio Occultation (GNSS-RO) observations for atmospheric and ionospheric monitoring, and thermospheric neutral density data for satellite orbit prediction.